HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dominique Figarella-Branger Selected Research

Medulloblastoma

1/2022Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse.
1/2021Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5.
12/2020Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
11/2020Medulloblastomas associated with an APC germline pathogenic variant share the good prognosis of CTNNB1-mutated medulloblastomas.
12/2018Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
8/2018Otx2 promotes granule cell precursor proliferation and Shh-dependent medulloblastoma maintenance in vivo.
11/2015Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial.
9/2012Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial.
11/2010Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis.
4/2009Online quality control, hyperfractionated radiotherapy alone and reduced boost volume for standard risk medulloblastoma: long-term results of MSFOP 98.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Dominique Figarella-Branger Research Topics

Disease

84Neoplasms (Cancer)
04/2022 - 05/2003
37Glioblastoma (Glioblastoma Multiforme)
01/2022 - 05/2004
33Glioma (Gliomas)
10/2022 - 02/2003
15Astrocytoma (Pilocytic Astrocytoma)
01/2021 - 11/2002
10Medulloblastoma
01/2022 - 04/2009
10Pituitary Neoplasms (Pituitary Adenoma)
09/2017 - 05/2003
9Meningioma (Meningiomas)
01/2021 - 08/2005
8Adenoma (Adenomas)
02/2016 - 05/2003
7Brain Neoplasms (Brain Tumor)
05/2016 - 02/2003
7Ependymoma
01/2016 - 10/2003
6Oligodendroglioma
01/2020 - 11/2002
6Carcinogenesis
08/2019 - 08/2009
5Growth Hormone-Secreting Pituitary Adenoma
06/2021 - 09/2007
5Necrosis
12/2019 - 08/2009
5Hypoxia (Hypoxemia)
01/2019 - 09/2010
5Neoplasm Metastasis (Metastasis)
05/2013 - 05/2003
4Disease Progression
06/2022 - 05/2004
4Acromegaly
06/2021 - 05/2003
4Pituitary ACTH Hypersecretion
08/2017 - 10/2006
4Neuroepithelial Neoplasms (Gliomatosis Cerebri)
01/2017 - 02/2003
4Inflammation (Inflammations)
04/2014 - 12/2003
4Myositis (Idiopathic Inflammatory Myopathies)
01/2013 - 12/2003
4Muscular Diseases (Myopathy)
11/2010 - 11/2005
3Primitive Neuroectodermal Tumors (PNET)
12/2018 - 09/2012
3Ganglioglioma
01/2018 - 09/2013
3Neuroendocrine Tumors (Neuroendocrine Tumor)
09/2017 - 05/2003
3ACTH-Secreting Pituitary Adenoma
09/2010 - 07/2003
3Dysferlinopathy
02/2009 - 08/2005
2Sarcoma (Soft Tissue Sarcoma)
01/2022 - 01/2013
2Genomic Instability
12/2019 - 05/2014
2B-Cell Lymphoma (Lymphoma, B Cell)
07/2014 - 10/2012
2Dermatomyositis (Dermatopolymyositis)
01/2013 - 08/2008
2Seizures (Absence Seizure)
10/2012 - 01/2012
2Drug Resistant Epilepsy
10/2012 - 11/2009
2Carcinoma (Carcinomatosis)
10/2010 - 05/2003
2Renal Cell Carcinoma (Grawitz Tumor)
11/2009 - 06/2003
2Osteosarcoma (Osteogenic Sarcoma)
08/2009 - 12/2007
2Protein Deficiency
02/2009 - 08/2007

Drug/Important Bio-Agent (IBA)

16Proteins (Proteins, Gene)FDA Link
01/2019 - 11/2005
14Messenger RNA (mRNA)IBA
01/2022 - 07/2003
12Biomarkers (Surrogate Marker)IBA
06/2022 - 10/2009
11Temozolomide (Temodar)FDA LinkGeneric
01/2021 - 05/2004
9Octreotide (Sandostatin)FDA LinkGeneric
01/2021 - 09/2007
9Pharmaceutical PreparationsIBA
01/2021 - 06/2012
9ProlactinIBA
01/2016 - 05/2003
8Bevacizumab (Avastin)FDA Link
04/2022 - 05/2012
8Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
07/2021 - 12/2008
8Biological ProductsIBA
12/2020 - 10/2008
8DNA (Deoxyribonucleic Acid)IBA
01/2020 - 09/2012
6Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA
01/2020 - 09/2010
5Growth Hormone (Somatotropin)IBA
06/2021 - 05/2003
5ParaffinIBA
01/2019 - 11/2015
5Formaldehyde (Formol)FDA Link
01/2019 - 11/2015
5Somatostatin Receptors (Somatostatin Receptor)IBA
01/2018 - 12/2008
5Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)IBA
03/2010 - 05/2003
42,6-dinitrotoluene (DNT)IBA
10/2022 - 01/2012
4Irinotecan (Camptosar)FDA LinkGeneric
04/2022 - 05/2012
4RNA (Ribonucleic Acid)IBA
11/2021 - 10/2018
4EverolimusFDA Link
01/2021 - 08/2015
4AntibodiesIBA
10/2013 - 12/2007
4AdrenomedullinIBA
07/2011 - 04/2005
3Mitochondrial DNA (mtDNA)IBA
01/2022 - 02/2008
3Dopamine (Intropin)FDA LinkGeneric
06/2021 - 01/2012
3Carmustine (FIVB)FDA Link
01/2021 - 10/2009
3TubulinIBA
02/2020 - 02/2013
3Histones (Histone)IBA
01/2020 - 10/2016
3VimentinIBA
05/2019 - 10/2006
3Adrenocorticotropic Hormone (ACTH)FDA Link
02/2016 - 04/2008
3Protein Isoforms (Isoforms)IBA
02/2013 - 11/2002
3Dopamine Agonists (Dopamine Agonist)IBA
05/2012 - 04/2010
3DysferlinIBA
02/2009 - 08/2005
2EpitopesIBA
04/2022 - 08/2019
2SteroidsIBA
02/2022 - 08/2011
2Matrix Metalloproteinase 2 (Gelatinase A)IBA
01/2022 - 03/2014
2ProdrugsIBA
02/2020 - 11/2016
2lisavanbulinIBA
02/2020 - 11/2016
2BAL27862IBA
02/2020 - 11/2016
2somatostatin receptor 2IBA
01/2020 - 01/2018
2Telomerase (Telomerase Reverse Transcriptase)IBA
11/2019 - 01/2018
2ProscillaridinIBA
01/2018 - 11/2014
2Transcription Factors (Transcription Factor)IBA
05/2016 - 03/2010
2GlucocorticoidsIBA
02/2016 - 09/2010
2Codon (Codons)IBA
01/2016 - 12/2011
2Neurofibromin 2 (Merlin)IBA
08/2015 - 01/2008
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
05/2014 - 01/2014
2CalciumIBA
02/2013 - 11/2005
2Alkylating AgentsIBA
06/2012 - 10/2009
2Glial Fibrillary Acidic ProteinIBA
02/2012 - 06/2009
2SynaptophysinIBA
02/2012 - 10/2006
2Hormones (Hormone)IBA
10/2010 - 04/2008
2polysialic acidIBA
03/2010 - 09/2007
2MethyltransferasesIBA
10/2009 - 04/2007

Therapy/Procedure

26Drug Therapy (Chemotherapy)
04/2022 - 05/2004
25Radiotherapy
01/2022 - 10/2003
24Therapeutics
01/2022 - 12/2003
3Electrodes (Electrode)
01/2016 - 11/2009
3Adjuvant Radiotherapy
09/2010 - 05/2007
2Precision Medicine
06/2022 - 12/2018
2Aftercare (After-Treatment)
01/2020 - 07/2010
2Craniospinal Irradiation
12/2018 - 04/2009